---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-25-000041"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:50:12.509116+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M

## Summary
- Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).
- Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.
- Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.
- Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.
- Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements.

## SEC filing metadata
- accession: 0001127537-25-000041
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/0001127537-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/lung-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-25-000041
- JSON: https://secwatch.observer/filing/0001127537-25-000041.json
- Plain text: https://secwatch.observer/filing/0001127537-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.